Remote Cardiac Rehabilitation for Congenital Heart Disease
(Remote-CaRe Trial)
Trial Summary
The trial does not specify if you need to stop taking your current medications, but it does exclude participants who are prescribed milrinone. If you are taking this medication, you would not be eligible to participate.
Research shows that remote cardiac rehabilitation, which includes exercise and digital support, is as effective as in-person programs for improving health outcomes in heart patients. It helps increase physical activity and quality of life, and can be especially beneficial for those who face barriers to attending traditional rehab programs.
12345Research shows that remote cardiac rehabilitation, including telehealth and home-based programs, is generally safe for people with heart conditions. Studies have evaluated its safety and feasibility, indicating it can be a safe alternative to traditional in-person programs.
26789Remote Cardiac Rehabilitation is unique because it allows patients to participate in cardiac rehab from home using telemedicine, which can be more convenient and accessible than traditional in-person programs. This approach is particularly beneficial during situations like the COVID-19 pandemic, where attending in-person sessions may be challenging.
110111213Eligibility Criteria
Adolescents aged 12-19 with specific congenital heart diseases, internet access at home, and cleared for exercise by their cardiologist. They must be available for in-home exercises during weekdays and not have conditions like uncontrolled asthma or reliance on a pacemaker.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Ramp-up
Participants engage in a 2-week ramp-up period with live health coach sessions
Treatment
Participants receive live-supervised, group-based exercise training via telehealth
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term Monitoring
Participants are encouraged to wear a physical activity monitor for a minimum of 6 months